
Zomedica Corp. ZOM
Geschäftsbericht 2025
hinzugefügt 16.03.2026
Zomedica Corp. Kurzfristige Verbindlichkeiten 2011-2026 | ZOM
Kurzfristige Verbindlichkeiten Jährlich Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.45 M | 9.33 M | 9.03 M | 7.81 M | 4.34 M | 2.03 M | 2.09 M | 2.38 M | 829 K | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 9.45 M | 829 K | 5.25 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
128 M | $ 18.88 | 1.51 % | $ 121 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.11 | 1.3 % | $ 43.7 M | ||
|
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | ||
|
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B | ||
|
Harrow Health
HROW
|
96.3 M | $ 36.38 | 2.68 % | $ 1.34 B | ||
|
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | ||
|
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | ||
|
Bausch Health Companies
BHC
|
4.3 B | $ 5.37 | 2.09 % | $ 1.96 B | ||
|
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.01 | 2.31 % | $ 109 M | ||
|
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.55 | 12.39 % | $ 336 M | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 23.11 | 2.57 % | $ 1.07 B | ||
|
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Evolus
EOLS
|
75.3 M | $ 4.17 | 2.21 % | $ 269 M | ||
|
Emergent BioSolutions
EBS
|
651 M | $ 8.28 | 5.21 % | $ 424 M | ||
|
Solid Biosciences
SLDB
|
33.5 M | $ 7.86 | 1.55 % | $ 688 M | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
Tilray
TLRY
|
433 M | $ 6.78 | 5.01 % | $ 4.19 B | ||
|
Veru
VERU
|
11.9 M | $ 2.51 | 1.21 % | $ 339 M | ||
|
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | ||
|
Viatris
VTRS
|
6.75 B | $ 13.57 | 3.08 % | $ 16.3 B | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 0.71 | -0.7 % | $ 3.06 M | ||
|
Relmada Therapeutics
RLMD
|
6.43 M | $ 6.88 | 1.93 % | $ 272 M | ||
|
Rockwell Medical
RMTI
|
9.58 M | $ 0.96 | 1.05 % | $ 34.5 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.31 | 4.53 % | $ 2.87 M | ||
|
SCYNEXIS
SCYX
|
5.73 M | $ 0.93 | -2.94 % | $ 46.4 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
7.4 M | $ 0.61 | 0.11 % | $ 2.62 M | ||
|
TherapeuticsMD
TXMD
|
4.78 M | $ 2.09 | 3.47 % | $ 24.2 M |